Hydrix Limited · ASX:HYD
Hydrix — Investor Presentation (February 2022)
17 slides from Hydrix's investor presentation, Feb 28, 2022
Slide 1: Capital Raising Presentation February 2022
For personal use only Capital Raising Presentation February 2022
Slide 2: Hydrix Medical, Services and Ventures
Hydrix Medical Sales of diagnostic, monitoring & interventional For personal use only cardiovascular products 2025 product revenue objective $50m Strategic focus on Hydrix Services cardiovascular technologies Design and engineering services transforming client needs into commercial products Client r
Slide 3: Executive Summary
Executive Summary • Diversified global medtech company – 20-year history in medtech product development, Melbourne based, global customers Company Overview • Three complementary business segments provide significant operating leverage For personal use only • Core strategic focus on technologies that
Slide 4: Hydrix Group: H1 FY22 Financials & Outlook
Hydrix Group: H1 FY22 Financials & Outlook Strong YoY client revenue growth, approaching significant medical product commercialisation milestones & venture investment uplifts For personal use only Client Services (Only) Revenue Growth ($m) Key Insights H1 FY22 Update COVID impact • Client services 1
Slide 5: Our strategic focus: cardiovascular disease
For personal use only CVD is the Our strategic focus No 1 Cause of death globally 18million 85% $70B+ Annual global CVD deaths CVD device CVD related caused by market by deaths 1 heart attacks 2027 2 or stroke 1 (1) World Health Organisation June 2021 5 (2) Global Industry Analysts, Inc Reports - Ap
Slide 6: Our growth objective
For personal use only Product Sales Our growth objective Three or more CVD devices Investment producing Returns +$50m revenues p.a. Design in 2025 Services 2021 2025 Product revenue growth is the catalyst to drive valuation prospects 6
Slide 7: Realising our objective: two product launches
For personal use only Realising our objective Product 1 Product 2 Implantable Continuous Heart Monitor Cardiovascular Surgery Device Well underway AngelMed Guardian Phyzhon FFR Real-time emergency cardiac Coronary guidewire with progressing event telemedicine (FDA integrated pressure sensor two prod
Slide 8: Summary
For personal use only Summary World class Product sales Board & TALENT into the leadership focused on US $70B TALENT with a improving CVD market proven a billion track lives record 8
Slide 9: CY22 Outlook: news flow and updates
For personal use only News flow and updates for CY2022: CY22 Outlook • Appendix 4C & Market Update (January) & 1HFY22 audited results (February) Progress • Uplift in valuations across the Ventures portfolio towards first • Independent Human Research Ethics Committee approval for a national commercia
Slide 10: Board & Senior Management Team
Board & Senior Management Team Hydrix’s board and leadership teams have the experience and drive to ensure the success of the Company For personal use only Hydrix Board Gavin Coote Paul Wright Joanne Bryant Julie King Alyn Tai Paul Lewis Executive Chairman Non-Executive Director Non-Executive Direct
Slide 11: Hydrix – a corporate snapshot
Hydrix – a corporate snapshot For personal use only Major Shareholders Shares (m) % Capital Structure (as of 23 February 2021) John W. King & related entities 18.9 11.5% Ticker HYD Patagorang 8.5 5. 1% Share Price $0.125 Invia Custodian 7.9 4.8% Shares on Issue (m) 164.6 Pusen Medical Technology Aus
Slide 12: Capital Raising – Offer Details & Timetable
Capital Raising – Offer Details & Timetable • Placement to raise approximately A$2.5m (with the ability to accept oversubscriptions up to $4m) under existing ASX L.R. 7.1 & 7.1A capacity • Participants in the Placement will be entitled to receive 1 free attaching option for every 1 share subscribed
Slide 13: Key Risks
Key Risks ▪ Ability to win and retain customers: the Company’s business is dependent on the securing of contracts to provide product design and engineering, and selling medical products under distribution agreements. The Company has no control over the timing of these opportunities or in respect of
Slide 14: International Offer Restrictions
International Offer Restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any
Slide 15: For personal use only
For personal use only
Slide 16: Important notice: not an offer document
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES For personal use only This presentation is dated 24 February 2022 and has been prepared and authorised by Hydrix Limited (ACN 060 369 048) (“Hydrix”) in connection with a placement of fully paid ordinary shares and attaching options in Hydrix (“Ne
Slide 17: Forward Looking Statements
FORWARD LOOKING STATEMENTS The information in this presentation is subject to change without notice and Hydrix is not obliged to update or correct it. This presentation contains statements that constitute "forward-looking statements". The forward-looking statements include statements regarding For p